Shandong Luoxin Pharmacy Group, Luoxin Biotechnology Shanghai Co. patent BRD4/1/2 inhibitors June 7, 2018
S1P regulation key for bone quality and may constitute a therapeutic target in osteoporosis June 7, 2018
FDA grants rare pediatric disease designation to CLR-131 for the treatment of rhabdomyosarcoma June 7, 2018
RSS